Point72 (DIFC)’s Vir Biotechnology VIR Stock Holding History

Point72 (DIFC)’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-26,917	Closed	-$240K	–	1858
2024 Q2	$240K	Buy	26,917 +17,941	+200%	+$172K	0.01%	810
2024 Q1	$90.9K	Buy	+8,976	New	+$91.4K	﹤0.01%	1103

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 (DIFC)'s VIR Position: Q3 2024 in Review

Point72 (DIFC) sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 26,917 shares — an estimated $240K sold.

Point72 (DIFC) first reported a position in VIR in Q1 2024 and held it in 2 quarters. The position peaked at $240K in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

Point72 (DIFC) reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
Point72 (DIFC) sold 26,917 Vir Biotechnology shares in Q3 2024, an estimated $240K.
Point72 (DIFC) first reported a position in Vir Biotechnology in Q1 2024 and held it in 2 quarters.
Point72 (DIFC)'s Vir Biotechnology position peaked at $240K in Q2 2024.
197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Point72 (DIFC)'s 13F filing for Q3 2024, filed 14 Nov 2024.